TY - JOUR
T1 - Nuclear receptors
T2 - From molecular mechanisms to therapeutics
AU - Frigo, Daniel E.
AU - Bondesson, Maria
AU - Williams, Cecilia
N1 - Funding Information:
D.E.F. has received research funding from GTx, Inc and has a familial relationship with Hummingbird Bioscience, Maia Biotechnology, Alms Therapeutics, Hinova Pharmaceuticals and Barricade Therapeutics. The other authors report no potential conflicts of interest. The funders had no role in the conceptualization or writing of the manuscript, or in the decision to publish this article.
Publisher Copyright:
© 2021 The Author(s).
PY - 2021/11
Y1 - 2021/11
N2 - Nuclear receptors are classically defined as ligand-activated transcription factors that regulate key functions in reproduction, development, and physiology. Humans have 48 nuclear receptors, which when dysregulated are often linked to diseases. Because most nuclear receptors can be selectively activated or inactivated by small molecules, they are prominent therapeutic targets. The basic understanding of this family of transcription factors was accelerated in the 1980s upon the cloning of the first hormone receptors. During the next 20 years, a deep understanding of hormone signaling was achieved that has translated to numerous clinical applications, such as the development of standard-of-care endocrine therapies for hormonally driven breast and prostate cancers. A 2004 issue of this journal reviewed progress on elucidating the structures of nuclear receptors and their mechanisms of action. In the current issue, we focus on the broad application of new knowledge in this field for therapy across diverse disease states including cancer, cardiovascular disease, various inflammatory diseases, the aging brain, and COVID-19.
AB - Nuclear receptors are classically defined as ligand-activated transcription factors that regulate key functions in reproduction, development, and physiology. Humans have 48 nuclear receptors, which when dysregulated are often linked to diseases. Because most nuclear receptors can be selectively activated or inactivated by small molecules, they are prominent therapeutic targets. The basic understanding of this family of transcription factors was accelerated in the 1980s upon the cloning of the first hormone receptors. During the next 20 years, a deep understanding of hormone signaling was achieved that has translated to numerous clinical applications, such as the development of standard-of-care endocrine therapies for hormonally driven breast and prostate cancers. A 2004 issue of this journal reviewed progress on elucidating the structures of nuclear receptors and their mechanisms of action. In the current issue, we focus on the broad application of new knowledge in this field for therapy across diverse disease states including cancer, cardiovascular disease, various inflammatory diseases, the aging brain, and COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85120947343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120947343&partnerID=8YFLogxK
U2 - 10.1042/EBC20210020
DO - 10.1042/EBC20210020
M3 - Review article
C2 - 34825698
AN - SCOPUS:85120947343
VL - 65
SP - 847
EP - 856
JO - Essays in Biochemistry
JF - Essays in Biochemistry
SN - 0071-1365
IS - 6
ER -